Our finding that increased arthritis flare was mildly associated with an increased percent Tregs out of live lymphocytes and that increasing IL-2 was associated with gains in Treg frequency and immunomodulatory markers suggests a potential opportunity for low-dose IL-2 as a novel therapy to target Tregs for post-CHIKV Treg deficiency. Here, IL2 is linked to arthritic joint disease.